ZURA BIO LIMITED Accounts Payable and Accrued Liabilities, Current
ZURA BIO LIMITED (ZURA) had Accounts Payable and Accrued Liabilities, Current of $16.32 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Accounts Payable and Accrued Liabilities, Current $16.32M.
- 2026-03-31: Accounts Payable and Accrued Liabilities, Current $11.74M.
- 2025-12-31: Accounts Payable and Accrued Liabilities, Current $12.41M.
- 2025-09-30: Accounts Payable and Accrued Liabilities, Current $25.49M.
| Period end | Accounts Payable and Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $16.32M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $11.74M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $12.41M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $25.49M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $18.70M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $21.09M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $19.51M 10-K · filed 2026-03-19 |
| 2024-09-30 | $18.24M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $15.07M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $14.67M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $20.30M 10-K · filed 2025-03-25 |
| 2023-09-30 | $17.01M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $19.94M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $4.99M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $4.43M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |